Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by B. Mark Evers
Cancer death rates have hit a 30-year low. Here’s how we got there | Opinion
Follow Cancer death rates have hit a 30-year low. Here’s how we got there | Opinion Cancer kills fewer Americans today than at any point in the past three decades. Since 1991, the overall cancer death rate in the U.S. has fallen 34%, a decline driven by expanded prevention and screening along with a new generation of treatments including targeted therapies and immunotherapies. These advances trace directly back to clinical trials — the research that turns scientific questions into standard care.
Tu1304 NEUROTENSIN PROMOTES INTESTINAL STEM CELL PROLIFERATION VIA NTSR1-MEDIATED UPREGULATION OF FIBROBLAST-DERIVED WNT LIGANDS
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Sa1432 PROINFLAMMATORY FACTORS CONTROL RSPO3 EXPRESSION IN INTESTINAL STROMAL CELLS THROUGH ACTIVATION OF P38 SIGNALING PATHWAY
Also available on ScienceDirect
RNA‐Micelles as Self‐Assembling Structures for Efficient Co‐Delivery of Synergistic siRNA and Nucleoside Analogues to Treat CRC Lung Metastasis
3WJ Three Way Junction AS Anti-Sense CH cholesterol EpC EpCAM Gem Gemcitabine MC Micelle S Sense SS Single Strand Sur Survivin siRNA 1 Introduction Colorectal cancer (CRC) ranks as the third most common cause of cancer death [3-5]. CRC metastasizes to distant organs, predominantly the lung and liver, and leads to only a 5 year survival rate of 16% [6-11]. CRC rapidly develops resistance to chemotherapeutics.
Guest columnist: Kentucky’s cancer progress hangs in the balance
State AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington D.C.West VirginiaWisconsinWyomingPuerto RicoUS Virgin IslandsArmed Forces AmericasArmed...
Kentucky’s cancer progress hangs in the balance
Kentucky is known for its resilience, and few stories demonstrate this better than our transformation when it comes to lung cancer. Our state has historically led the nation in lung cancer rates, but since 2013 — when the University of Kentucky Markey Cancer Center first achieved National Cancer Institute designation — the rate of late-stage lung cancer has declined at double the national rate.
Progress fighting cancer threatened by cuts
Kentucky is known for its resilience and few stories demonstrate this better than our transformation when it comes to lung cancer. Our state historically has led the nation in lung cancer rates, but since 2013 — when the University of Kentucky Markey Cancer Center first achieved National Cancer Institute designation — the rate of late-stage lung cancer has declined at double the national rate.
Kentucky’s cancer progress hangs in the balance
Kentucky is known for its resilience, and few stories demonstrate this better than our transformation when it comes to lung cancer. Our state has historically led the nation in lung cancer rates, but since 2013 — when the University of Kentucky Markey Cancer Center first achieved National Cancer Institute designation — the rate of late-stage lung cancer has declined at double the national rate.
Kentucky’s cancer progress hangs in the balance
Personalised advertising and content, advertising and content measurement, audience research and services development Store and/or access information on a device You can choose how your personal data is used.
Kentucky’s cancer progress hangs in the balance
Kentucky is known for its resilience, and few stories demonstrate this better than our transformation when it comes to lung cancer. Our state has historically led the nation in lung cancer rates, but since 2013 — when the University of Kentucky Markey Cancer Center first achieved National Cancer Institute designation — the rate of late-stage lung cancer has declined at double the national rate.
Kentucky has made huge strides in fighting cancer. NIH cuts threaten that progress | Opinion
AI-generated summary reviewed by our newsroom Kentucky cut late-stage lung cancer rates at twice the national average since 2013. NIH funding supports over 370 cancer research projects and 90 clinical trials in KY. Proposed NIH cuts risk delaying trials, reducing screenings, and losing progress gains. Kentucky is known for its resilience, and few stories demonstrate this better than our transformation when it comes to lung cancer.
Glycogen drives tumour initiation and progression in lung adenocarcinoma - Nature Metabolism
Abstract Lung adenocarcinoma (LUAD) is an aggressive cancer defined by oncogenic drivers and metabolic reprogramming. Here we leverage next-generation spatial screens to identify glycogen as a critical and previously underexplored oncogenic metabolite. High-throughput spatial analysis of human LUAD samples revealed that glycogen accumulation correlates with increased tumour grade and poor survival.
GDP-mannose 4,6-dehydratase is a key driver of MYCN-amplified neuroblastoma core fucosylation and tumorigenesis - Oncogene
Abstract MYCN-amplification is a genetic hallmark of ~40% of high-risk neuroblastomas (NBs). Altered glycosylation is a common feature of adult cancer progression, but little is known about how genetic signatures such as MYCN-amplification alter glycosylation profiles. Herein, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) revealed increased core fucosylated glycan abundance within neuroblast-rich regions of human MYCN-amplified NB tumors.
UK Markey Cancer Center is breaking cancer’s grip. But there’s still a long way to go.
When I think about cancer in Kentucky, I am proud of the tremendous strides we have made to loosen the grip of this terrible disease on our people. But I also know that we have a long way to go. The University of Kentucky Markey Cancer Center is the go-to cancer center in the state as the only National Cancer Institute (NCI)-designated center in the commonwealth. We have made incredible progress in advancing medicine and cancer research.
Cancer in Kentucky: Why Research Matters
When I think about cancer in Kentucky, I am proud of the tremendous strides we have made to loosen the grip of this terrible disease on our people. But I also know that we have a long way to go. The University of Kentucky Markey Cancer Center is the go-to cancer center in the state as the only National Cancer Institute (NCI)-designated center in the Commonwealth. We have made incredible progress in advancing medicine and cancer research.
Small C-terminal domain phosphatase enhances snail activity through dephosphorylation
Comment Journal of Biological Chemistry (2009) - pubmed: 19004823 doi: 10.1074/jbc.m806916200 issn: 0021-9258 issn: 1083-351x Yadi Wu, B. Mark Evers, Binhua P. Zhou
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with B. Mark
Contact B. Mark, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack